Faiez Zannad from France presented the results of the Phase 1/2b EXCELLENT trial, demonstrating that intramyocardial injections of autologous expanded CD34+ stem cells (ProtheraCytes) for the treatment of Acute Myocardial Infarction (AMI) promote reverse remodeling. This evidence concerns the gene CD34 and myocardial infarction.